Organogenesis (ORGO) Expected to Release Earnings on Thursday

Organogenesis (NASDAQ:ORGO) is expected to be releasing its Q3 2026 results after the market closes on Thursday, November 5th. Analysts expect the company to announce earnings of ($0.1750) per share and revenue of $52.10 million for the quarter. Individuals can check the company’s upcoming Q3 2026 earnings overview page for the latest details on the call scheduled for Thursday, November 5, 2026 at 5:00 PM ET.

Organogenesis (NASDAQ:ORGO) last issued its earnings results on Thursday, August 6th. The company reported ($0.71) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.35) by ($0.36). Organogenesis had a negative return on equity of 23.89% and a negative net margin of 19.94%. The firm had revenue of $43.76 million during the quarter, compared to the consensus estimate of $54.27 million.

Organogenesis Stock Performance

NASDAQ ORGO opened at $0.83 on Wednesday. The company has a fifty day simple moving average of $1.32 and a 200 day simple moving average of $2.35. The company has a debt-to-equity ratio of 0.07, a current ratio of 3.52 and a quick ratio of 3.00. Organogenesis has a 12-month low of $0.73 and a 12-month high of $7.08.

Wall Street Analyst Weigh In

A number of research analysts have weighed in on ORGO shares. Weiss Ratings lowered shares of Organogenesis from a “sell (d-)” rating to a “sell (e+)” rating in a research note on Monday, October 19th. Wall Street Zen upgraded shares of Organogenesis from a “strong sell” rating to a “sell” rating in a report on Saturday, September 19th. Finally, Truist Financial decreased their target price on shares of Organogenesis from $3.00 to $2.00 and set a “hold” rating for the company in a research report on Friday, August 7th. Two equities research analysts have rated the stock with a Hold rating and one has given a Sell rating to the company’s stock. According to MarketBeat, the company has an average rating of “Reduce” and an average target price of $4.33.

Organogenesis Company Profile

Organogenesis Holdings Inc is a biotechnology company that develops, manufactures and commercializes products intended to support tissue regeneration and wound healing. The company serves the advanced wound care and surgical and sports medicine markets, with a focus on therapies that help manage complex wounds and support the repair of damaged tissue.

Its product portfolio includes bioengineered skin substitutes and other biologic products, such as Apligraf, Dermagraft, NuShield, Affinity and NuCel.